MX2023015021A - Mimeticos de hepcidina para el tratamiento de la hemocromatosis hereditaria. - Google Patents

Mimeticos de hepcidina para el tratamiento de la hemocromatosis hereditaria.

Info

Publication number
MX2023015021A
MX2023015021A MX2023015021A MX2023015021A MX2023015021A MX 2023015021 A MX2023015021 A MX 2023015021A MX 2023015021 A MX2023015021 A MX 2023015021A MX 2023015021 A MX2023015021 A MX 2023015021A MX 2023015021 A MX2023015021 A MX 2023015021A
Authority
MX
Mexico
Prior art keywords
treatment
hereditary hemochromatosis
hepcidin mimetics
hepcidin
mimetics
Prior art date
Application number
MX2023015021A
Other languages
English (en)
Spanish (es)
Inventor
David Y Liu
Suneel Kumar Gupta
Nishit Bachulal Modi
Frank Horace Valone
Original Assignee
Protagonist Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protagonist Therapeutics Inc filed Critical Protagonist Therapeutics Inc
Publication of MX2023015021A publication Critical patent/MX2023015021A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
MX2023015021A 2021-06-14 2022-06-14 Mimeticos de hepcidina para el tratamiento de la hemocromatosis hereditaria. MX2023015021A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163210453P 2021-06-14 2021-06-14
US202163252001P 2021-10-04 2021-10-04
US202263349841P 2022-06-07 2022-06-07
PCT/US2022/033378 WO2022266060A1 (en) 2021-06-14 2022-06-14 Hepcidin mimetics for treatment of hereditary hemochromatosis

Publications (1)

Publication Number Publication Date
MX2023015021A true MX2023015021A (es) 2024-01-26

Family

ID=84527344

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023015021A MX2023015021A (es) 2021-06-14 2022-06-14 Mimeticos de hepcidina para el tratamiento de la hemocromatosis hereditaria.

Country Status (11)

Country Link
US (1) US20240293511A1 (cg-RX-API-DMAC10.html)
EP (2) EP4355763A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024520861A (cg-RX-API-DMAC10.html)
KR (1) KR20240021833A (cg-RX-API-DMAC10.html)
AU (1) AU2022293672A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023026381A2 (cg-RX-API-DMAC10.html)
CA (1) CA3220871A1 (cg-RX-API-DMAC10.html)
IL (1) IL309166A (cg-RX-API-DMAC10.html)
MX (1) MX2023015021A (cg-RX-API-DMAC10.html)
TW (1) TW202317604A (cg-RX-API-DMAC10.html)
WO (1) WO2022266060A1 (cg-RX-API-DMAC10.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4091624A1 (en) 2013-03-15 2022-11-23 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
CA2949215C (en) 2014-05-16 2023-03-14 Protagonist Therapeutics, Inc. .alpha.4.beta.7 integrin thioether peptide antagonists
SG10201810154WA (en) 2014-07-17 2018-12-28 Protagonist Therapeutics Inc Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
WO2018022937A1 (en) 2016-07-27 2018-02-01 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 and their use to treat inflammatory diseases
WO2019157268A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
MX2022008740A (es) 2020-01-15 2022-09-23 Janssen Biotech Inc Peptidos inhibidores del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
SMT202500254T1 (it) 2020-01-15 2025-09-12 Janssen Biotech Inc Inibitori peptidici del recettore dell'interleuchina-23 e loro uso per trattare malattie infiammatorie
AU2021383828A1 (en) 2020-11-20 2023-07-06 Janssen Pharmaceutica Nv Compositions of peptide inhibitors of interleukin-23 receptor
KR20240034224A (ko) 2021-07-14 2024-03-13 얀센 바이오테크 인코포레이티드 인터류킨-23 수용체의 지질화된 펩티드 억제제
WO2025207760A1 (en) * 2024-03-27 2025-10-02 Protagonist Therapeutics, Inc. Formulations of a hepcidin peptide analogue

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4091624A1 (en) 2013-03-15 2022-11-23 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
KR20170002414A (ko) 2014-04-07 2017-01-06 멀겐져 바이오텍, 아이엔씨. 헵시딘 모방 펩티드 및 그 용도
AU2015279571A1 (en) * 2014-06-27 2017-02-02 Protagonist Therapeutics, Inc. Hepcidin and mini-hepcidin analogues and uses therof
WO2016109363A1 (en) * 2014-12-29 2016-07-07 The Regents Of The University Of California S-Alkylated Hepcidin Peptides and Methods of Making and Using Thereof
WO2017068089A2 (en) 2015-10-23 2017-04-27 Vifor (International) Ag Novel ferroportin inhibitors
CA3009834A1 (en) * 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
AU2017324446A1 (en) 2016-09-06 2019-03-28 La Jolla Pharmceutical Company Methods of treating iron overload
WO2018128828A1 (en) 2016-12-23 2018-07-12 Bayer Healthcare Llc Novel hepcidin mimetics and uses thereof
US20220372099A1 (en) * 2019-09-03 2022-11-24 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics

Also Published As

Publication number Publication date
AU2022293672A1 (en) 2023-12-14
JP2024520861A (ja) 2024-05-24
BR112023026381A2 (pt) 2024-03-05
AU2022293672A9 (en) 2024-01-11
TW202317604A (zh) 2023-05-01
KR20240021833A (ko) 2024-02-19
IL309166A (en) 2024-02-01
EP4355763A4 (en) 2025-07-30
WO2022266060A1 (en) 2022-12-22
EP4737477A2 (en) 2026-05-06
EP4355763A1 (en) 2024-04-24
US20240293511A1 (en) 2024-09-05
CA3220871A1 (en) 2022-12-22

Similar Documents

Publication Publication Date Title
PH12022551013A1 (en) Pyridazinones as parp7 inhibitors
BR112023026381A2 (pt) Miméticos de hepcidina para tratamento de hemocromatose hereditária
JOP20220083A1 (ar) حلقات غير متجانسة ثنائية الحلقة كمثبطات لـ fgfr
PH12021551686A1 (en) Pcsk9 inhibitors and methods of use thereof
IL286636A (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES OR DISORDERS RELATED TO KRAS
NZ770260A (en) Substituted heterocyclic inhibitors of ptpn11
MA42560B1 (fr) Compositions comprenant des souches bactériennes de blautia pour le traitement de l'hypersensibilité viscérale
MY205416A (en) Tyk2 inhibitors and uses thereof
MX2024001243A (es) Composiciones y metodos para el tratamiento de melanoma.
SG11202010089QA (en) Compositions and methods for treatment of iron overload
PH12021552588A1 (en) Cd73 inhibitors
EP4225923A4 (en) COMPOSITIONS AND METHODS FOR PREVENTING AND/OR TREATING COVID-19
PH12022551377A1 (en) Vegf mini-traps and method of use thereof
WO2020021477A3 (en) Compositions and methods for treating the eye
MX2019011506A (es) Inhibicion de cinasa 1 de punto de control (chk1) para el tratamiento de cancer.
SA522431538B1 (ar) طُرق وتركيبات لعلاج تساقط الشعر
WO2022020353A3 (en) Methods and compositions for treatment and prevention of coronavirus infection
WO2020021480A3 (en) Compositions and methods for treating the eye
GEP20094677B (en) Combination of src kinase inhibitors and chemotherapeutic agents for treatment of proliferative diseases
WO2023114847A3 (en) Compositions and methods for treating disease
WO2020163782A3 (en) Immunotherapy for the treatment and prevention of inflammatory bowel disease
WO2021257770A3 (en) Sars-cov-2 immunodominant peptides and uses thereof
AU2020378127A8 (en) Compounds as CD73 inhibitors
MX2022015552A (es) Prevencion, reduccion o mejora del olor a persona mayor.
PH12018501646A1 (en) Compositions and methods for treating infections